Perspective Therapeutics updates corporate presentation with pipeline progress and 2026 data expectations

Perspective Therapeutics, Inc.

Lead programs VMT-α-NET (SSTR2+ NETs), VMT01 (MC1R melanoma), PSV359 (FAP-α) all in Phase 1/2a trials.
Proprietary 212Pb-based radioligand platform and chelator designed for broader use; manufacturing underway.
Phase 1/2 data expected across all three clinical programs in 2026.
Preliminary anti-tumor activity observed for VMT01 at lower dose; well-tolerated safety profile.
VMT-α-NET shows compelling anti-tumor activity and best-in-class safety; potential registration study at current dose.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.